Skip to main content
SpringerLink
Log in

Should we really worry about “launch delays” of new drugs in OECD countries?

  • Editorial
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vernon, J.A.: Examining the link between price regulation and pharmaceutical R&D investment. Health Econ. 14, 1–16 (2005)

    Article  Google Scholar 

  2. Danzon, P.M., Wang, I.L., Wang, L.: The impact of price regulation on the launch delay of new drugs—evidence from twenty five major markets in the 1990s. Health Econ. 14, 269–295 (2005)

    Article  Google Scholar 

  3. Lanjow, J.O.: Patents, price controls and access to new drugs: how policy affects global market entry. NBER working paper no. 11321 (May 2005)

  4. Kyle, M.K.: Pharmaceutical price controls and entry strategies. Duke university working paper (2005)

  5. Lichtenberg, F.: Do (more and better) drugs keep people out of hospitals? Am. Econ. Rev. 86, 384–388 (1996)

    Google Scholar 

  6. Lichtenberg, F.: The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982–2001. Int. J. Health Care Financ. Econ. 5, 47–73 (2005)

    Article  Google Scholar 

  7. Kessler, D.P.: The effects of pharmaceutical price controls on the cost and quality of medical care: a review of the empirical literature. US Department of Commerce and International Trade Administration (http://www.ita.doc.gov/td/health/–)

  8. Prescrire International: A review of new drugs and indications in 2002: financial speculation or better patient care? Prescrire Int. 12(64), 74–77 (2003)

    Google Scholar 

  9. Joppi, R., Bertelè, V., Garattini, S.: Disappointing biotech. BMJ 331, 895–897 (2005)

    Article  Google Scholar 

  10. Apolone, G., Joppi, R., Bertelè, V., Garattini, S.: Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br. J. Cancer 93, 504–509 (2005)

    Article  Google Scholar 

  11. Garattini, S., Garattini, L.: Drugs sales in four European countries still differ. BMJ 327, 1404–1405 (2003)

    Article  Google Scholar 

  12. US Department of Commerce, International Trade Administration (December 2004) Pharmaceutical price controls in OECD countries

Download references

Author information

Authors and Affiliations

  1. CESAV, Center for Health Economics, Mario Negri Institute for Pharmacological Research, Villa Camozzi-Via Camozzi,3, 24020, Ranica, Italy

    Livio Garattini & Simone Ghislandi

  2. Department of Economics, University of Oxford, Oxford, UK

    Simone Ghislandi

Authors
  1. Livio Garattini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simone Ghislandi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Livio Garattini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garattini, L., Ghislandi, S. Should we really worry about “launch delays” of new drugs in OECD countries?. Eur J Health Econ 8, 1–3 (2007). https://doi.org/10.1007/s10198-006-0022-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-006-0022-5

Search

Navigation